These studies suggest that pre-existing immune profiles may dictate the likelihood of a given tumor to respond to anti-PD-L1, consistent with clinical data showing that increased CD8 TILs before ICI treatment correlated with better responses and survival (76). Here, CD8A is linked to neoplasm.